Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Golden Throat Holdings Group Co Ltd ( (HK:6896) ) just unveiled an announcement.
Golden Throat Holdings reported a sharp deterioration in 2025 results, with revenue falling 20.4% year on year to RMB943.3 million and gross profit down 19.8% to RMB717.0 million. Earnings before interest, taxes, depreciation and amortisation dropped 22.9% to RMB377.1 million, while profit attributable to shareholders slid 21.2% to RMB251.2 million, translating into basic earnings per share of RMB33.98 cents versus RMB43.10 cents a year earlier.
Despite the downturn, the board is recommending a final dividend of HK$0.34 per share for 2025, subject to shareholder approval at the upcoming annual general meeting. The maintained payout underlines the company’s continued emphasis on shareholder returns, even as weaker sales and profitability may raise concerns about demand dynamics and cost pressures in its core healthcare consumer products business.
The most recent analyst rating on (HK:6896) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on Golden Throat Holdings Group Co Ltd stock, see the HK:6896 Stock Forecast page.
More about Golden Throat Holdings Group Co Ltd
Golden Throat Holdings Group Company Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the healthcare and consumer products sector, best known for throat lozenges and related products. The group focuses on the mainland China market, where it derives the bulk of its revenue from the manufacture and sale of branded lozenge and healthcare items.
Average Trading Volume: 811,158
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$2.64B
See more insights into 6896 stock on TipRanks’ Stock Analysis page.